LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
MCRB
Seres Therapeutics, Inc.
There isn't enough reported data to score MCRB yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
MCRB Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Weak | |
| Unavailable |
MCRB's profitability and cash flow are currently weak. There isn't enough data to rate its revenue and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
MCRB PE Valuation
MCRB has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
MCRB Forward outlook
There aren't enough analyst estimates for MCRB to show an outlook.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over MCRB on earnings quality, reporting a profit while its opponent remains loss making.
MCRB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$5.02 | -910% |
| Q2 2026 | -$2.45 | -122% |
| Q1 2026 | -$5.19 | -157% |
| Q4 2025 | $0.64 | +$0.64 |
| Q3 2025 | $0.62 | +$5.02 |
| Q2 2025 | $11.28 | +$34.68 |
| Q1 2025 | $9.15 | +$20.95 |
| Q4 2024 | $0.00 | +$17.71 |
MCRB has swung to a loss: it lost $5.02 per share over the past year, after a profit the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over MCRB on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over MCRB on profitability, with a higher operating margin.
MCRB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $593K | +69% |
| Q4 2023 | $64K | -93% |
| Q3 2023 | $310K | -91% |
| Q2 2023 | $126.5M | +10301% |
| Q4 2022 | $975K | -86% |
| Q3 2022 | $3.4M | -97% |
| Q2 2022 | $1.2M | -77% |
| Q1 2022 | $1.5M | -74% |
MCRB's revenue is recovering but still below its 2021 peak: $593,000 last quarter, up 69% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2724% | +3680 points |
| Q2 2026 | -2890% | N/A |
| Q1 2026 | -5840% | N/A |
| Q4 2025 | -4424% | N/A |
| Q3 2025 | -6404% | N/A |
| Q4 2023 | -61759% | -54754 points |
| Q3 2023 | -15295% | -13578 points |
| Q2 2023 | 39% | +5247 points |
MCRB's operating margin was −2724% last quarter, up 3680 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over MCRB on cash generation, producing positive trailing cash flow while its opponent burns cash.
MCRB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$10.5M | -577% |
| Q2 2026 | -$22.4M | -$8.9M |
| Q1 2026 | -$16.4M | -161% |
| Q4 2025 | -$14.7M | +$24.2M |
| Q3 2025 | $2.2M | +$37M |
| Q2 2025 | -$13.5M | +$26.4M |
| Q1 2025 | $26.9M | +$62.2M |
| Q4 2024 | -$39M | +$9.4M |
MCRB has burned cash in almost every quarter: −$64M over the past year, against −$23M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over MCRB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
MCRB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.4% | +235K shares |
| 1 year | +14% | +1.2M shares |
| 3 years | +56% | +3.6M shares |
| 5 years | +110% | +5.2M shares |
| Available history | +182% | +6.4M shares |
MCRB has 10M diluted shares, up 14% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2023 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
MCRB Net Leverage
MCRB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
MCRB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.5 | Oversold |
| Stochastic | 3.9 | Oversold |
MCRB's weekly RSI is 25 (oversold) and its Stochastic is 4 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
MCRB PE vs Healthcare Sector
| Metric | MCRB | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
MCRB has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over MCRB on trend strength, trading above more of its moving averages.
MCRB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.36 | 40% below |
| 20 week MA | $4.08 | 65% below |
| 50 week MA | $7.91 | 82% below |
| 100 week MA | $11.2 | 87% below |
| 200 week MA | $29.8 | 95% below |
MCRB is in a downtrend: it's below all five of its weekly moving averages, and 95% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over MCRB on returns for 2026, with the stronger performance.
MCRB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $80.0 | $485.6 | +507% |
| 2021 | $485.6 | $183.4 | -62% |
| 2022 | $183.4 | $104.8 | -43% |
| 2023 | $104.8 | $28.0 | -73% |
| 2024 | $28.0 | $17.7 | -37% |
| 2025 | $17.7 | $14.7 | -17% |
| 2026 YTD | $14.7 | $1.41 | -90% |
MCRB has finished five years in a row lower, and it's down 90% so far in 2026.